Straumann Holding Ag · SIX:STMN
Straumann — FY2025 Earnings Presentation
46 slides from Straumann's earnings presentation, Feb 18, 2026
Slide 1: 2025 Full-Year Results
2025 FULL-YEAR RESULTS Presentation for investors, analysts and media Basel, February 18, 2026
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements ar
Slide 3: Agenda
AGENDA 1 2025 performance overview Guillaume Daniellot 2 2025 financial performance Isabelle Wege 3 Strategy update & 2026 priorities Guillaume Daniellot 4 2026 outlook Guillaume Daniellot 5 Q&A Guillaume Daniellot & Isabelle Wege 3
Slide 4: 2025 Performance Overview
2025 PERFORMANCE OVERVIEW – Guillaume Daniellot, Group CEO – 4
Slide 5: 7.3 million smiles in 2025
OUR PURPOSE IS TO UNLOCK THE POTENTIAL OF PEOPLE’S LIVES our success in number of smiles 7.3 million smiles in 2025 1 Increase of 600 000 from last year 1 Source: Straumann Group; calculation per smile: 2 implants or 1 clear aligner case start
Slide 6: Strong organic revenue growth of 8.9%
STRONG ORGANIC REVENUE GROWTH OF 8.9% Continuous market share gains, growth and profitability progressed in line with guidance Revenue in 2025 Organic revenue growth in 2025 EBIT margin at constant currency1 2.6bn 8.9% 26.5% CHF 655.0 m revenue in Q4 or 4.1% in CHF and Core EBIT margin 25.2% 7.0% or
Slide 7: Strong growth across regions with varied market dynamics
STRONG GROWTH ACROSS REGIONS WITH VARIED MARKET DYNAMICS NAM EMEA Regional % share of FY 25 4.2% FY 25 11.2% organic growth Q4 25 6.8% Q4 25 15.3% 13 NAM 42 %* 26 %* 17 LATAM GROUP FY 25 8.9% 19 APAC FY 24 13.7% 9 %* 23 %* Q4 25 7.0% Q4 24 11.5% LATAM APAC 51 EMEA FY 25 18.3% FY 25 7.3% Q4 25 20.0%
Slide 8: 2025 Financial Performance
2025 FINANCIAL PERFORMANCE – Isabelle wEge, Group CFO – 8
Slide 9: Translating strong growth into profitability
TRANSLATING STRONG GROWTH INTO PROFITABILITY Revenue to free cash flow bridge FY 20251 Highlights – we delivered on our guidance Strong gross margin driven by diversified portfolio, revenue 2.6BN scale effects and favorable product mix Gross profit 1.8BN Focus on execution and efficiency measures de
Slide 10: Gross profit margin at 70.1% remains on a high level
GROSS PROFIT MARGIN AT 70.1% REMAINS ON A HIGH LEVEL Thanks to improved profitability despite tariffs and growth investments in %, rounded 0.2 71.2 -50 bps 70.6 -0.8 -0.1 70.1 -0.4 68.6 -1.5 IFRS gross Non-core items FX effect CORE gross Mix, Productivity Shanghai CORE gross Non-core items IFRS gros
Slide 11: Core EBIT margin increased to 25.2%
CORE EBIT MARGIN INCREASED TO 25.2% EBIT margin amounting to 26.5% at constant 2024 currency exchange rates in %, rounded +50 bps 2.0 1.2 25.2 24.7 24.0 -0.1 -1.3 -0.5 21.1 -4.1 IFRS EBIT Non-core items FX effect CORE EBIT Gross profit Efficiency gains Other CORE EBIT Non-core items IFRS EBIT margin
Slide 12: Core net result reached CHF 478 m
CORE NET RESULT1 REACHED CHF 478 M Core net result margin 18.3% in CHF million, rounded +7.2% 66 502 -18 478 -5 -11 446 -56 358 -120 CORE Net FX effect CORE Net EBIT Financial result Associates result Income tax CORE Net Non-core items IFRS Net Profit FY 2024 Profit FY 2024 Profit FY 2025 Profit FY
Slide 13: Strong cash position
STRONG CASH POSITION While maintaining high investments into manufacturing capacity and innovation in CHF million, rounded Free cash flow1 CAPEX CHF 290m (11.1% of net revenue) in FY 2025 CHF 223m (8.6% of net revenue) in FY 2025 +26.6% 504 -274 475 375 -130 Cash Net cash operating Net cash investin
Slide 14: Further increase in dividend
FURTHER INCREASE IN DIVIDEND Proposed dividend of CHF 1.00 per share +5% • Payable on 23 April 2026 (ex-dividend: 21 April 2026) 1.000 • Core payout ratio of 33.4% 0.950 0.850 0.800 0.675 0.575 0.575 0.525 0.475 0.400 0.425 0.375 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 14 Cash di
Slide 15: Sustainability strategy delivering measurable progress
SUSTAINABILITY STRATEGY DELIVERING MEASURABLE PROGRESS Advancing access, reducing environmental impact, building resilience 42% EDUCATION ACTIVITIES IN LOW-AND -17%* CO2 EMISSIONS (scope 1+2) 98.5% RENEWABLE ELECTRICITY MIDDLE-INCOME COUNTRIES vs. 2021 *Improved data quality and enhanced calculation
Slide 16: Strategy Update
STRATEGY UPDATE – Guillaume Daniellot, Group CEO – 16
Slide 17: Increased market share from 12.5% to 14%
INCREASED MARKET SHARE FROM 12.5% TO 14% Gains in all segments and still huge opportunities ahead in a CHF 20 bn addressable market Perform Transform Implantology Clear aligner Market size Market size >35% (+1%) CHF 6.1BN <5% CHF 4.9BN Market share Market share RegenerativeS Digital equipment Market
Slide 18: Our playbook for growth to outperform the market
OUR PLAYBOOK FOR GROWTH TO OUTPERFORM THE MARKET Innovation, digitalization, education 1 Expand 2 transform 3 Disrupt implant leadership Ortho franchise Chairside prosthetics Partnership 18
Slide 19: Accelerating growth through product and experience
ACCELERATING GROWTH THROUGH PRODUCT AND EXPERIENCE 50% product leadership. 50% customer experience. Innovation Digitalization drives product excellence enhances efficiency & clinician experience Expanding clinical Enhancing Improving clinical Seamless end-to- Driving productivity Standardizing appli
Slide 20: 1 Expand implant leadership
1 EXPAND IMPLANT LEADERSHIP 20
Slide 21: Massive growth potential due to low implant penetration
MASSIVE GROWTH POTENTIAL DUE TO LOW IMPLANT PENETRATION Estimated 220 million patients per year who could afford an implant treatment Global Implant penetration per 10’000 adult inhabitants HUGE 900 800 MARKET OPPORTUNITY 700 AHEAD 600 500 Benchmark 400 300 200 100 0 South Korea Spain Italy France B
Slide 22: iEXCEL – strongest implant launch in company history
IEXCEL – STRONGEST IMPLANT LAUNCH IN COMPANY HISTORY Advancing performance through next-generation systems Innovation iEXCEL: > 1 million implants sold in 2025 High traction in immediacy & full-arch workflows New customer acquisition especially from the value segment 22
Slide 23: Neodent drives geographical expansion globally
NEODENT DRIVES GEOGRAPHICAL EXPANSION GLOBALLY And market share gains in the value segment Innovation ~ 5 million Grand Morse implants sold in 2025 Significant geographical global expansion Registration for China expected in 2027 23
Slide 24: Building a strong comprehensive advantage
BUILDING A STRONG COMPREHENSIVE ADVANTAGE Straumann AXS – our successful open platform technology Digitalization Straumann aXS open cloud-based platform Smile in a box Straumann AXS scaled from 0 to above 15 000 codiagnostix active users within 18 months Integrated digital workflows drive simplicity
Slide 25: Redefining implantology through digital integration
REDEFINING IMPLANTOLOGY THROUGH DIGITAL INTEGRATION iEXCEL, AHA and AXS – seamlessly connected for optimized outcomes Digitalization 26Weeks Patient time saved 50 MINUTES of clinical chairtime saved 52 Appointments 1: iExcel 2: Place AHA 3: Scan AHA 4: Restore Straumann FAST Molar Solution 25
Slide 26: Leading position in driving implant penetration
LEADING POSITION IN DRIVING IMPLANT PENETRATION Expanding market access through education and drive implant clinical adoption Education 10 700 education programs delivered globally >370 000 dental professionals trained worldwide Education and clinical networks expand market accessibility and drive i
Slide 27: 2 Transform Ortho franchise
2 TRANSFORM ORTHO FRANCHISE 27
Slide 28: Transformation of ClearCorrect value proposition
TRANSFORMATION OF CLEARCORRECT VALUE PROPOSITION Strategic partnerships to accelerate market share gains Innovation Enhanced aligner design features, including Scalloped trimline scalloped trimline, improve clinical handling and For clinician preference patient comfort Expanded innovation portfolio
Slide 29: New integrated technology to differentiate
NEW INTEGRATED TECHNOLOGY TO DIFFERENTIATE Digital workflows enabling broader general practitioner (GP) adoption Digitalization Clearcorrect RemoteCare Powered by: Supporting GP with case conversion CBCT integration Enhanced treatment planning through CBCT Before/after simulation integration Faster
Slide 30: Supporting growth through education
SUPPORTING GROWTH THROUGH EDUCATION Education Education-driven enablement accelerates GP adoption and scalable case growth ClearCorrect Ortho Campus provides structured, modular education Online and clinical treatment support 30
Slide 31: 3 Disrupt chairside prosthetics
3 DISRUPT CHAIRSIDE PROSTHETICS 31
Slide 32: Outgrowing the market – strong market share gains
OUTGROWING THE MARKET – STRONG MARKET SHARE GAINS Intraoral scanners are the entry point into our digital ecosystem Innovation New sirios x3 intraoral scanner IOS portfolio – multi branding & multi pricing 3Shape Premium TRIOS 5/6 Mid SIRIOS X3 Straumann aXS open cloud-based platform Entry SIRIOS 32
Slide 33: Disrupting prosthetic through digital
DISRUPTING PROSTHETIC THROUGH DIGITAL Unlocking prosthetics with end-to-end digital workflows Digitalization Full ai automated crown design within Straumann AXS Fast! 3 crowns, inlays or onlays in less than 10 minutes Innovative chairside resin portfolio in a patented capsule format Enabling a consu
Slide 34: Culture
CULTURE straumanngroup
Slide 35: Our culture turns VUCA into a competitive advantage
OUR CULTURE TURNS VUCA INTO A COMPETITIVE ADVANTAGE Engagement score of 80 reflects our high-performance player-learner culture 80 ENGAGEMENT SCORE our Core beliefs 35
Slide 36: 2026 Outlook
2026 OUTLOOK – Guillaume Daniellot, Group CEO – 36
Slide 37: Outlook 2026 – well-positioned
OUTLOOK 2026 – WELL- POSITIONED 1 Expected volatility and regulatory • High-single digit organic revenue environment to persist growth Resilient business model with strong market positions • 30 to 60 basis points improvement Highly engaged, entrepreneurial culture of the core EBIT margin at co
Slide 38: Any questions?
ANY QUESTIONS? 38
Slide 39: Annual Report Published
Annual Report 2025 Published 39 today
Slide 40: Calendar of upcoming events
CALENDAR OF UPCOMING EVENT 2026 Event Location February 19–20 Swiss Roadshow – UBS Zurich and Geneva March 3 Morgan Stanley Healthcare Conference London March 3–5 US Roadshow – William Blair New York and Boston March 4 UBS Healthcare Conference London March 9–10 Paris Roadshow – BNP Exane Paris Marc
Slide 41: Thank you
THANK YOU. 41
Slide 42: Strong results despite considerable FX headwinds
STRONG RESULTS DESPITE CONSIDERABLE FX HEADWINDS Revenue development breakdown (in CHF million, rounded) +4.1% +8.9% Regional % share Organic of organic growth 36 2,605 41 13 NAM 27 17 LATAM 2,504 109 19 APAC 0 2,392 -112 Change in organic growth 51 EMEA +11.2% +4.2% +7.3% +18.3% Revenue FX effect M
Slide 43: Core results reconciliation
CORE RESULTS RECONCILIATION (in CHF 1 000) IFRS M&A Impairments Restructuring Legal cases Associates 1 CORE Revenue 2 605 393 0 0 0 0 0 2 605 393 Cost of goods sold (818 539) 123 0 39 334 0 0 (779 082) Gross profit 1 786 855 123 0 39 334 0 0 1 826 311 Other income 11 308 0 0 419 0 0 11 727 Distribut
Slide 44: Full-year 2025 core financials at a glance
FULL-YEAR 2025 CORE FINANCIALS AT A GLANCE Core net profit rose 25% to 477 million at constant currencies FY 20251 % of Revenue Change in % CER2 Margin Change CER2 REVENUE 2 605 +8.9% COGS -779 29.9% GROSS PROFIT 1 826 70.1% +8.1% -50 bps Operating expenses -1 183 45.4% Other Result 12 0.5% EBIT 655
Slide 45: Full-year 2025 IFRS financials at a glance
FULL-YEAR 2025 IFRS FINANCIALS AT A GLANCE Core net profit rose 6% to 357 million at constant currencies FY 20251 % of Revenue Change in % CER2 Margin Change CER2 REVENUE 2 605 +8.9% COGS -819 31.4% GROSS PROFIT 1 787 68.6% +6.0% -190 bps Operating expenses -1 249 47.9% Other Result 11 0.4% EBIT 549
Slide 46: Currency exposure
CURRENCY EXPOSURE Revenue breakdown FY 2025 Exchange rates development 2023 – 2025 110.00 CHF 1% 105.00 Other 21% EUR 100.00 26% 95.00 BRL 6% 90.00 85.00 CNY 80.00 15% USD/CAD/AUD 75.00 30% 70.00 12/2023 03/2024 06/2024 09/2024 12/2024 03/2025 06/2025 09/2025 12/2025 USDCHF EURCHF CNYCHF BRLCHF Tota